Lupin receives USFDA approval for Tolvaptan Tablets
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This product will be manufactured at Lupin's Pithampur facility in India
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
Subscribe To Our Newsletter & Stay Updated